Becton Dickinson Raises Annual Profit Forecast, Beats Q2 Estimates on Strong Device Sales
BDX sits 16% above its 52-week low of $127.536.
Summary
Becton Dickinson (BDX) significantly raised its annual adjusted profit per share forecast to $12.52-$12.72, up from its previous range of $12.35-$12.65, driven by robust demand for its drug-delivery devices and surgical equipment. The company also reported strong second-quarter results, with adjusted EPS of $2.90 on $4.71 billion in revenue, both exceeding analyst estimates of $2.77 and $4.67 billion, respectively. Additionally, Becton Dickinson formally appointed Vitor Roque as its Executive Vice President and Chief Financial Officer. This positive financial performance and improved outlook are material for the large-cap medical technology company, signaling strong operational momentum and likely to boost investor confidence. The news also briefly referenced the earlier spin-off of its biosciences and diagnostic solutions unit in a deal with Waters Corp (WAT).
At the time of this announcement, BDX was trading at $147.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $41.2B. The 52-week trading range was $127.54 to $187.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.